Camillo langone biography of mahatma gandhi

  • Mahindra University · Main School of Fire Service · Makerere College School (MACOS) · Makerere University · Makerere.
  • The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care.
  • Biography.
  • Editors

    Scientific Reports is run by a team of experienced editors who are experts in their fields. From our Editorial Board Members and Senior Editorial Board to our in-house Editors, we work togetherResearch integrity issue to ensure that your research is expertly handled and that we consider it to be technically sound, scientifically valid, and ultimately suitable for publication.


    Interview with Rafal Marszalek, Chief Editor of Scientific Reports








     

     

    In-house Editors

    Chief Editor: Rafal Marszalek, PhD; Springer Nature, UK

    Rafal's background is analytical and biological chemistry. He did his PhD and postdoctoral research in single-cell proteomics at Imperial College London, UK. He was an editor at Genome Biology before joining Scientific Reports in August 2016.

    ORCID 0000-0003-0316-1363

    Deputy Editor: Elizabeth Mann, PhD; Springer Nature, UK

    Elizabeth has a background in pharmacology and completed her PhD in neuropharmacology at King's Col

    A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)

    J3M-MC-JZQB - ClinicalTrials.gov - NCT06119581

    The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C.

    Trial Summary

    Key Requirements

    Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

    Participants Must:

    • Have non-small cell lung cancer that is advanced or has spread to another part(s) of the body

    • Have cancer with a change in the KRAS G12C gene

    • Have a known programmed death-ligand&nbs

    • camillo langone biography of mahatma gandhi
    • Invited speakers and organizers
      Martin A. Green

      The University of New South Wales, Australia

      Australia

      Martin A. Green

      The University of New South Wales, Australia, AU

      Martin Green fryst vatten currently a Scientia Professor at the University of New South Wales and Director of the Australian National Energy Agency (ARENA) supported Centre for Advanced Photovoltaics. He was formerly a Director of CSG Solar, a company formed specifically to commercialise the University’s thin-film, polycrystalline-silicon-on-glass solar cell. His group's contributions to photovoltaics are well known including the development of the world’s highest efficiency silicon solar cells and the successes of several spin-off companies.

      ERKAN AYDIN

      University of Munich (LMU), Department of Chemistry and Center for Nanoscience (CeNS)

      Germany

      ERKAN AYDIN

      Department of Chemistry

      University of Munich (LMU), Department of Chemistry and Center for Nanoscience (CeNS), DE